ALDX at a glance
Aldeyra Therapeutics, Inc. (ALDX, SEC CIK 1341235) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Aldeyra Therapeutics, Inc. (ALDX) shares worth $12.4 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by DEPTULA-HICKS DARLENE M on November 12, 2026 of 7,500 shares at $0.65 per share.
- In the last 90 days, ALDX insiders reported 3 open-market purchases ($140K) and 0 open-market sales ($0) on Form 4, a net purchase of $140K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$140K
- 13F holders
- 21 funds
- $12.4M · −2 vs prior quarter
- Latest 8-K
- Nov 17, 2026
- Item 3.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Regulatory risk: 2026 Complete Response Letter triggered FDRR submission on October 26, 2026, with uncertain timing and approval outcome
- Operational risk: Third-party reproxalap manufacturer received Form 483 deficiencies in August 2025, later classified VAI
- Competitive risk: Dry-eye market includes Restasis, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo, Vevye, and Tryptyr
- Financial risk: Nine-month 2026 net loss $12.7 million, accumulated deficit $496.6 million, requiring substantial additional financing
- Legal risk: FDA “radical transparency” policy creates potential Securities Class Action and SEC scrutiny following public Complete Response Letters
Management Discussion & Analysis
- Quarterly revenue: $0, with no approved products and no product sales revenue
- Net loss $3.8M vs $7.7M YoY, loss from operations $4.1M vs $8.0M
- Reproxalap: primary late-stage R&D focus, approximately 30% of quarterly R&D expenses
- Cash $41.0M at September 30, 2026, operating cash use $13.8M year-to-date
- FDA Complete Response Letter and FDRR pending, ADX-2191 retinitis pigmentosa program suspended, AbbVie option unexercised
AI summary of the ALDX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum
- No immediate delisting, Nasdaq listing remains effective
Item 8.01: Other Events
- FDA review-jurisdiction transfer requested from Ophthalmology to Hematologic Malignancies 2 for ADX-2191’s PVRL program
- SPA protocol withdrawn, eliminating prior FDA agreement on trial design and planned analysis
Item EX-99.1: Item EX-99.1
- Aldeyra plans a Formal Dispute Resolution Request to FDA’s Office of New Drugs after three complete response letters for reproxalap
- OND meeting expected in Q4 2026, but FDRR timing and outcome remain uncertain
Item 7.01: Regulation FD Disclosure
- Aldeyra plans to appeal FDA’s March 16, 2026 rejection of reproxalap’s dry-eye NDA through a Formal Dispute Resolution Request
- FDRR submission and FDA Office of New Drugs meeting expected in Q4 2026, creating a potential approval-pathway catalyst
Item EX-99.2: Item EX-99.2
- Aldeyra plans an FDA Formal Dispute Resolution Request in Q4 2026 to appeal reproxalap’s March 16, 2026 rejection for dry eye disease
- Regulatory risk remains high: three Complete Response Letters, with the latest citing insufficient totality of evidence rather than requesting another trial
Item 8.01: Other Events
- Aldeyra plans an FDA dispute resolution request challenging the March 16, 2026 rejection of reproxalap for dry eye disease
- Reproxalap approval remains uncertain, creating a regulatory catalyst and significant binary risk for investors
AI summaries of ALDX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALDX
Don't miss the next ALDX filing
- Alerts as it files. A push when ALDX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALDX, by share count.
- Ask anything. An AI agent that reads every ALDX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DEPTULA-HICKS DARLENE M | Buy | Nov 12, 2026 | 7,500 | $0.65 |
| DOUGLAS RICHARD | Buy | Nov 11, 2026 | 200,000 | $0.64 |
| Alfieri Michael | Buy | Nov 11, 2026 | 10,000 | $0.65 |
| Miller-Rich Nancy | A | Jun 9, 2026 | 3,318 | - |
| Bronstein Ben | A | Jun 9, 2026 | 4,977 | - |
| DOUGLAS RICHARD | A | Jun 9, 2026 | 70,000 | - |
| Bronstein Ben | A | Jun 9, 2026 | 5,309 | - |
| DOUGLAS RICHARD | A | Jun 9, 2026 | 2,323 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$42.8M | -$60.1M | -$35.3M | |
| Net Income | -$37.5M | -$55.9M | -$33.8M | |
| Balance Sheet | ||||
| Total Assets | $148.3M | $104.6M | $72.1M | |
| Equity | $119.8M | $71.0M | $44.3M | |
| ROE | -31.3% | -78.7% | -76.5% | |
| Per Share | ||||
| EPS | $-0.64 | $-0.94 | $-0.56 | |
| Cash Flow | ||||
| Operating CF | -$30.3M | -$43.2M | -$33.3M | |
| CapEx | $0 | - | - | |
Source: XBRL data in Aldeyra Therapeutics, Inc. (ALDX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ALDX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $12.4M |
| Q2 2026 | 23 | $31.1M |
| Q1 2026 | 23 | $29.6M |
| Q4 2025 | 23 | $81.1M |
| Q3 2025 | 24 | $83.1M |
| Q2 2025 | 25 | $51.9M |
| Q1 2025 | 23 | $54.2M |
| Q4 2024 | 17 | $40.9M |
- D.E. Shaw & Co+274.2K (+14%)
- Vanguard Capital Management LLC+31.0K (+1%)
- Invesco Ltd+24.7K (+15%)
- Bank of America Corp+15.9K (+47%)
- Vanguard Portfolio Management LLC+12.5K (+2%)
- AQR Capital Management−3.08M (-82%)
- Goldman Sachs Group−452.6K (-62%)
- Dimensional Fund Advisors−319.1K (-60%)
- Millennium Management−298.6K (-83%)
- BlackRock−260.4K (-21%)
- FMR LLC (Fidelity)−17.9K
- PNC Financial Services−1.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALDX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 17, 2026 | - | Analysis | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| SC 13G | Aug 12, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 1, 2026 | - | Analysis | - |
| 8-K | Apr 20, 2026 | - | Analysis | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 4 | Mar 31, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ALDX SEC filings: frequently asked questions
Are ALDX insiders buying or selling?
In the last 90 days, Aldeyra Therapeutics, Inc. (ALDX) officers, directors and 10% owners reported 3 open-market purchases worth $140,275 by 3 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALDX stock?
As of September 30, 2026, the largest Aldeyra Therapeutics, Inc. (ALDX) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.9 million), D.E. Shaw & Co ($2.7 million), BlackRock ($1.2 million), Vanguard Portfolio Management LLC ($993,000), AQR Capital Management ($827,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What did ALDX report in its latest 8-K?
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K on November 17, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum.
What are the latest ALDX SEC filings?
Aldeyra Therapeutics, Inc. (ALDX) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on November 16, 2026.
What is ALDX's SEC CIK number?
Aldeyra Therapeutics, Inc. (ALDX)'s SEC Central Index Key (CIK) is 1341235. EDGAR lists every ALDX filing under that number.
Ask anything about ALDX
The research agent reads ALDX's filings, financials, insider trades and 13F holders, then answers with sources.